Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Beam Therapeutics Inc (BEAM) PT Lowered to $60 at RBC Capital
November 7, 2022 10:51 AM ESTRBC Capital analyst Luca Issi lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $60.00 (from $76.00) while maintaining a Sector Perform rating.
The analyst comments "BEAM is prioritizing the lead HbF-boosting SCD program over the next-gen Makassar. We caught up... More
Beam Therapeutics Inc (BEAM) PT Lowered to $103 at Stifel
November 7, 2022 9:32 AM ESTStifel analyst Benjamin Burnett lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $103.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "We are reiterating our Buy rating on BEAM following 3Q22 updates. Main pushbacks from bears have been on (potentially... More
